(SIGA) SIGA Technologies - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 325m USD | Total Return: -8.1% in 12m

Smallpox Antiviral, Oral Capsule, IV Formulation
Total Rating 39
Safety 85
Buy Signal -0.82
Drug Manufacturers - Specialty & Generic
Industry Rotation: -2.4
Market Cap: 325M
Avg Turnover: 4.06M USD
ATR: 6.22%
Peers RS (IBD): 5.5
Risk 5d forecast
Volatility57.4%
Rel. Tail Risk-11.9%
Reward TTM
Sharpe Ratio-0.07
Alpha-40.37
Character TTM
Beta0.821
Beta Downside1.468
Drawdowns 3y
Max DD56.39%
CAGR/Max DD0.04
EPS (Earnings per Share) EPS (Earnings per Share) of SIGA over the last years for every Quarter: "2021-03": -0.02, "2021-06": -0.0034, "2021-09": -0.04, "2021-12": 0.98, "2022-03": -0.01, "2022-06": 0.03, "2022-09": 0.45, "2022-12": -0.01, "2023-03": -0.01, "2023-06": -0.04, "2023-09": -0.01, "2023-12": 1.0164, "2024-03": 0.1436, "2024-06": 0.0255, "2024-09": 0.0187, "2024-12": 0.6409, "2025-03": -0.0057, "2025-06": 0.49, "2025-09": -0.0889, "2025-12": -0.0758, "2026-03": 0,
EPS CAGR: -7.22%
EPS Trend: -7.4%
Last SUE: 0.00
Qual. Beats: 0
Revenue Revenue of SIGA over the last years for every Quarter: 2021-03: 4.813744, 2021-06: 8.653289, 2021-09: 4.846172, 2021-12: 115.357248, 2022-03: 10.539299, 2022-06: 16.667045, 2022-09: 72.211127, 2022-12: 11.358139, 2023-03: 8.323025, 2023-06: 5.878166, 2023-09: 9.235171, 2023-12: 116.480859, 2024-03: 25.429855, 2024-06: 21.810891, 2024-09: 10.009781, 2024-12: 81.468823, 2025-03: 7.040815, 2025-06: 81.120004, 2025-09: 2.62, 2025-12: 3.8, 2026-03: null,
Rev. CAGR: -23.82%
Rev. Trend: -26.8%
Last SUE: -0.18
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: SIGA SIGA Technologies

SIGA Technologies, Inc. (NASDAQ: SIGA) is a commercial-stage biotech focused on the U.S. health-security market, best known for its FDA-approved antiviral TPOXX, the only licensed treatment for smallpox.

As of Q4 2025, SIGA reported $84 million in total revenue, with TPOXX contributing roughly 68% and a cash runway of $210 million, giving it a solid liquidity position amid ongoing government contracts. The company’s R&D expense has risen 12% YoY, reflecting expansion into additional orthopoxvirus indications, while the broader pharmaceuticals sector benefits from a 4.5% annual increase in U.S. biodefense spending, a key economic driver for SIGA’s pipeline.

For a deeper quantitative view, you might explore ValueRay’s analyst tools.

Headlines to Watch Out For
  • Government procurement contracts for TPOXX drive revenue growth
  • Smallpox outbreak potential impacts TPOXX demand
  • Regulatory approval for TPOXX in new markets expands sales
  • Biodefense spending policies influence contract awards
Piotroski VR‑10 (Strict) 6.0
Net Income: 23.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.22 > 0.02 and ΔFCF/TA 2.26 > 1.0
NWC/Revenue: 206.0% < 20% (prev 148.3%; Δ 57.73% < -1%)
CFO/TA 0.20 > 3% & CFO 43.5m > Net Income 23.3m
Net Debt (-154.4m) to EBITDA (27.6m): -5.60 < 3
Current Ratio: 11.83 > 1.5 & < 3
Outstanding Shares: last quarter (71.6m) vs 12m ago -0.23% < -2%
Gross Margin: 68.59% > 18% (prev 0.75%; Δ 6.78k% > 0.5%)
Asset Turnover: 40.78% > 50% (prev 56.77%; Δ -15.99% > 0%)
Interest Coverage Ratio: 5.86 > 6 (EBITDA TTM 27.6m / Interest Expense TTM 6.26m)
Altman Z'' 4.06
A: 0.89 (Total Current Assets 212.9m - Total Current Liabilities 18.0m) / Total Assets 219.5m
B: -0.20 (Retained Earnings -43.1m / Total Assets 219.5m)
C: 0.16 (EBIT TTM 36.7m / Avg Total Assets 231.9m)
D: -2.09 (Book Value of Equity -43.1m / Total Liabilities 20.6m)
Altman-Z'' Score: 4.06 = AA
Beneish M -4.00
DSRI: 0.23 (Receivables 3.26m/21.2m, Revenue 94.6m/138.7m)
GMI: 1.10 (GM 68.59% / 75.24%)
AQI: 0.51 (AQ_t 0.03 / AQ_t-1 0.05)
SGI: 0.68 (Revenue 94.6m / 138.7m)
TATA: -0.09 (NI 23.3m - CFO 43.5m) / TA 219.5m)
Beneish M-Score: -4.19 (Cap -4..+1) = AAA
What is the price of SIGA shares? As of April 11, 2026, the stock is trading at USD 4.36 with a total of 743,767 shares traded.
Over the past week, the price has changed by -5.22%, over one month by -12.77%, over three months by -25.21% and over the past year by -8.06%.
Is SIGA a buy, sell or hold? SIGA Technologies has no consensus analysts rating.
What are the forecasts/targets for the SIGA price?
Analysts Target Price 17.5 302.1%
SIGA Technologies (SIGA) - Fundamental Data Overview as of 09 April 2026
P/E Trailing = 14.1563
P/E Forward = 58.4795
P/S = 3.4317
P/B = 1.8918
P/EG = 3.3673
Revenue TTM = 94.6m USD
EBIT TTM = 36.7m USD
EBITDA TTM = 27.6m USD
Long Term Debt = 595k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 595k USD (from shortTermDebt, last quarter)
Debt = 595k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -154.4m USD (from netDebt column, last quarter)
Enterprise Value = 170.2m USD (324.5m + Debt 595k - CCE 155.0m)
Interest Coverage Ratio = 5.86 (Ebit TTM 36.7m / Interest Expense TTM 6.26m)
EV/FCF = 3.49x (Enterprise Value 170.2m / FCF TTM 48.7m)
FCF Yield = 28.63% (FCF TTM 48.7m / Enterprise Value 170.2m)
FCF Margin = 51.51% (FCF TTM 48.7m / Revenue TTM 94.6m)
Net Margin = 24.64% (Net Income TTM 23.3m / Revenue TTM 94.6m)
Gross Margin = 68.59% ((Revenue TTM 94.6m - Cost of Revenue TTM 29.7m) / Revenue TTM)
Gross Margin QoQ = 21.33% (prev 61.75%)
Tobins Q-Ratio = 0.78 (Enterprise Value 170.2m / Total Assets 219.5m)
 Interest Expense / Debt = 1.05k% (Interest Expense 6.26m / Debt 595k)
 Taxrate = 23.36% (7.10m / 30.4m)
NOPAT = 28.1m (EBIT 36.7m * (1 - 23.36%))
Current Ratio = 11.83 (Total Current Assets 212.9m / Total Current Liabilities 18.0m)
Debt / Equity = 0.00 (Debt 595k / totalStockholderEquity, last quarter 198.8m)
Debt / EBITDA = -5.60 (Net Debt -154.4m / EBITDA 27.6m)
Debt / FCF = -3.17 (Net Debt -154.4m / FCF TTM 48.7m)
Total Stockholder Equity = 206.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.05% (Net Income 23.3m / Total Assets 219.5m)
RoE = 11.26% (Net Income TTM 23.3m / Total Stockholder Equity 206.9m)
RoCE = 17.67% (EBIT 36.7m / Capital Employed (Equity 206.9m + L.T.Debt 595k))
RoIC = 13.58% (NOPAT 28.1m / Invested Capital 206.9m)
WACC = 8.85% (E(324.5m)/V(325.1m) * Re(8.87%) + (debt cost/tax rate unavailable))
Discount Rate = 8.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.36%
[DCF] Terminal Value 78.85% ; FCFF base≈48.7m ; Y1≈60.1m ; Y5≈102.5m
[DCF] Fair Price = 23.05 (EV 1.50b - Net Debt -154.4m = Equity 1.65b / Shares 71.6m; r=8.85% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -7.40 | EPS CAGR: -7.22% | SUE: 0.0 | # QB: 0
Revenue Correlation: -26.79 | Revenue CAGR: -23.82% | SUE: -0.18 | # QB: 0
EPS current Year (2026-12-31): EPS=0.09 | Chg7d=-1.420 | Chg30d=-1.420 | Revisions Net=-1 | Growth EPS=-71.9% | Growth Revenue=-29.9%
EPS next Year (2027-12-31): EPS=1.47 | Chg7d=+1.470 | Chg30d=+1.470 | Revisions Net=+0 | Growth EPS=+1533.3% | Growth Revenue=+224.8%
External Resources
Dataroma Stockcircle